Autoimmune Neurology
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about how our movement disorders testing can help diagnose testicular cancer-associated paraneoplastic encephalitis.
Learn more about how our testing protocol is useful in the diagnosis of sorbitol dehydrogenase (SORD) deficiency.
Find out how we use glycine receptor Ab as a marker of stiff-person syndrome spectrum disorder.
Learn more about the risks of false positives with AQP4 ELISA methodology in CNS demyelinating disease testing.
Learn how a phenotype-specific autoimmune neurology evaluation diagnosed a treatable autoimmune encephalitis condition that was missed with a traditional paraneoplastic evaluation.
Find out how our testing uses neurofascin 155 IgG4 antibodies as a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy.
Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.
This webinar will discuss how autoimmune neurology testing has changed with expanding antibody discovery and why a patient-first, phenotype-specific approach improves test selection and interpretation.
In this presentation, Eoin Flanagan, M.B., B.Ch., a leading specialist in neuroimmunology at Mayo Clinic, provides a clear and clinically focused overview of autoimmune conditions that affect the developing nervous system.
Learn more about how Precision Epilepsy testing at Mayo Clinic Laboratories enables a holistic diagnostic care experience that supports better outcomes for patients with epilepsy.
Mayo Clinic Laboratories invites you to explore our latest microlearning on neuromyelitis optica spectrum disorder (NMOSD). In this concise educational module, Sean Pittock, M.D., explains the critical role of AQP4-IgG testing in the early diagnosis and treatment of NMOSD.
In this video, Dr. Vijay Ramanan shares perspectives on rational approaches to testing in the cognitive neurology, mild cognitive impairment, and dementia settings.